Recent developments include leadership changes, financing activities, a proposed reverse merger, and a corporate name and ticker change reflecting strategic repositioning.

• In February 2025, GridAI Technologies Corp. appointed Richard Paolone as interim CEO [N3].
• The company secured a $2 million loan and appointed new board members in February 2025 [N4].
• In November 2024, the company announced a proposed reverse merger with Journey Therapeutics [N5].
• In late November 2025, the company’s stock gained 5% ahead of its name change from Entero Therapeutics to GridAI Technologies Corp. [N2].
• Biotech sector momentum was noted in after-hours trading including Entero, reflecting market interest around the company [N1].

GridAI Technologies Corp. has developed a unique AI data center energy orchestration platform that integrates multiple energy assets and market participation, targeting a growing market of hyperscale AI data centers. The company's strategic pivot to focus on this niche, combined with its proprietary technology and ongoing business development efforts, positions it to capture emerging opportunities in energy optimization. The divestiture of legacy biopharmaceutical programs allows management to concentrate resources on the core technology platform. Recent leadership appointments and financing activities support operational continuity and growth initiatives.

GridAI Technologies Corp. faces significant challenges including the early development stage of its AI data center platform with no current revenue, limited liquidity with a low current ratio and cash ratio, and intense competition from established and emerging energy management providers. The company depends heavily on third-party hardware and software integration, which may pose operational risks. The commercial pipeline is nascent with no major customers, and the company must convert pilot programs into commercial contracts amid evolving regulatory and market conditions. Legacy biopharmaceutical programs have been discontinued or divested, reducing diversification. These factors contribute to execution and financial risks.

GridAI Technologies Corp.'s moat is based on its proprietary AI-optimized energy orchestration platform designed specifically for large-scale AI data centers, integrating distributed energy resources with real-time monitoring, digital twin modeling, and market participation capabilities. The platform's integration of data center operations with energy optimization and its co-optimization engine for energy markets provide a differentiated solution in a competitive landscape. The company's early-stage development and strategic partnerships with energy infrastructure participants contribute to its positioning. However, the moat is challenged by competition from established energy management providers, evolving regulatory frameworks, and the need to convert pilot programs into long-term commercial contracts.

• Early Stage Commercialization: Grid AI Corp.'s AI data center platform is in the development stage with no current revenue, creating execution risk in achieving commercial adoption.
• Liquidity Constraints: As of March 31, 2026, the company has limited liquidity with a current ratio of 0.16 and cash ratio of 0.02, which may impact its ability to fund operations and growth.
• Competitive Market: The company operates in a highly competitive market with established energy management providers and emerging entrants, which may pressure pricing and market share.
• Dependence on Third-Party Hardware and Software: The platform relies on integration with third-party hardware components and cloud infrastructure, exposing the company to supply chain and operational risks.
• Regulatory and Market Uncertainties: The company's solutions operate within regulated energy markets, requiring compliance with evolving regulatory frameworks and market rules, which may affect deployment and operations.

• GridAI Technologies Corp. (ticker GRDX) was formerly known as Entero Therapeutics, Inc. and changed its name and ticker effective December 1, 2025 [S1].
• The company operates two principal areas: (i) energy orchestration and grid optimization software solutions through its subsidiary Grid AI Corp., and (ii) legacy biopharmaceutical development activities centered on Adrulipase for exocrine pancreatic insufficiency [S1].
• Grid AI Corp. develops software and services to optimize energy infrastructure for AI data centers and other large energy users, focusing on distributed energy resources such as battery energy storage, on-site generation, and grid interconnections [S1].
• Grid AI Corp. is in the development stage of an AI data center platform with no current revenue from this platform; commercial pipeline is developing through consulting-led engagements and business development initiatives [S1].
• The company completed a share exchange transaction on September 30, 2025, acquiring 100% of Grid AI Corp., which owns 75% of AMPX UK Holdings, consolidated subsidiaries of GridAI Technologies Corp. [S1].
• Grid AI Corp.'s platform includes data integration, real-time monitoring, a proprietary digital twin model, forecasting models, and a co-optimization engine for energy markets, targeting enterprise and government customers operating large data center campuses [S1].
• Grid AI Corp. faces competition from established energy management software providers, virtual power plant platforms, battery system integrators, utilities, engineering firms, and in-house customer solutions; competition factors include software functionality, integration, regulatory expertise, and pricing [S1].
• The company has pivoted its strategy in 2025 to focus on energy orchestration for hyperscale AI data center campuses, reducing headcount and scaling back prior platforms to minimum support levels [S1].
• Grid AI Corp. plans to generate revenue from its AI data center platform through base platform fees for operational visibility and orchestration, and performance-based fees tied to power cost optimization [S1].
• GridAI Technologies Corp. retains legacy biopharmaceutical development activities focused on Adrulipase, a recombinant lipase enzyme for exocrine pancreatic insufficiency, including cystic fibrosis and chronic pancreatitis [S1].
• The company has discontinued or divested prior biopharmaceutical programs including Latiglutenase, CypCel, Niclosamide, and Capeserod; ImmunogenX was disposed of on December 31, 2025 [S1].
• Financial snapshot as of 2026-03-31 includes cash and equivalents of $385,542, current assets of $2,584,427, current liabilities of $16,231,727, resulting in a current ratio of 0.16 and cash ratio of 0.02 [S2].
• For the fiscal year ended December 31, 2025, the company reported a net loss of $6,392,654 [S1].
• Basic and diluted earnings per share were both -$0.82 for the quarter ended March 31, 2026 [S2].
• The company had 6,200,051 shares of common stock outstanding as of May 1, 2026 [S1].
• Recent leadership changes include appointment of Richard Paolone as interim CEO in February 2025 [N3].
• The company secured a $2 million loan and appointed new board members in February 2025 [N4].
• The company announced a proposed reverse merger with Journey Therapeutics in November 2024 [N5].
• The company changed its name from Entero Therapeutics to GridAI Technologies Corp. and ticker from ENTO to GRDX in late 2025 [N2].
• The company’s commercial pipeline for the AI data center platform is developing with discussions primarily with battery energy storage system providers and energy infrastructure participants [S1].
• The company’s business model relies significantly on software deployment, system integration, and third-party hardware ecosystems rather than traditional manufacturing [S1].
• Grid AI Corp. depends on third-party suppliers for hardware components such as control devices, gateways, and communications modules [S1].
• The company’s energy orchestration services depend on integration with devices, utilities, aggregators, and market operators, relying on a network of integration partners and cloud infrastructure [S1].
• The company does not currently have major customers for its AI data center platform and aims to serve AI data center developers and hyperscalers in the future [S1].
• The company’s liquidity ratios as of 2026-03-31 indicate limited short-term liquidity with a current ratio of 0.16 and cash ratio of 0.02 [S2].
• The company’s risk factors include high competition, reliance on third-party hardware and software, regulatory and market uncertainties, and the early stage of commercialization of its AI data center platform [S1].
• Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].